52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
37
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.

Shandong University
3
Discovery of a Dual PRMT5-PRMT7 Inhibitor.

University of Toronto
55
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design.

Tango Therapeutics
9
From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy.

Amgen
28
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.

Amgen
64
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.

Tango Therapeutics
24
Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.

Nanjing University of Chinese Medicine
2
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.

GlaxoSmithKline
2
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.

Daiichi Sankyo Co., Ltd
12
An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor.

Purdue University
28
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity.

AstraZeneca
2
Is it still worth renewing nucleoside anticancer drugs nowadays?

Jilin University
48
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers.

Tango Therapeutics
61
Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions.

China Pharmaceutical University
10
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.

University of Salerno
12
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.

Sun Yat-Sen University
47
Development of Macrocyclic PRMT5-Adaptor Protein Interaction Inhibitors.

Max Planck Institute of Molecular Physiology
35
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of

Mirati Therapeutics
33
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

The Broad Institute of Mit and Harvard
17
A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode.

Janssen Pharmaceutica
3
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.

Icahn School Of Medicine At Mount Sinai
16
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Epizyme
33
Pharmacophore-based screening of diamidine small molecule inhibitors for protein arginine methyltransferases.

University of Georgia
11
Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).

Merck
45
Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.

Shanghai Institute of Materia Medica
42
Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.

Prelude Therapeutics
37
Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.

University of Jinan
6
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.

Prelude Therapeutics
10
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.

Sun Yat-Sen University
2
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.

Lilly Research Laboratories
10
Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.

University of Jinan
59
PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS

Chiesi Farmaceutici
31
GPR35 Agonist Compounds

Heptares Therapeutics Limited
42
Peptide derivatives and uses thereof

Nosopharm
4
Amino alcohol derivative, pharmaceutical composition and application thereof

Beijing Foreland Pharma
2
NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF

Novo Nordisk
2
Deuterated compounds as rock inhibitors

Fochon Pharmaceuticals
14
Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

The Johns Hopkins University
186
Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist

Beigene
56
Compounds useful as RET inhibitors

Cancer Research Technology
205
Imidazotriaines and imidazopyrimidines as kinase inhibitors

Incyte Holdings
88
Compositions for treating neurodegenerative diseases

Cognition Therapeutics
80
Ectonucleotidase inhibitors and methods of use thereof

Calithera Biosciences
83
AMINOIMIDAZOLE FPR2 AGONISTS

Bristol Myers Squibb
14
Azaspiro[4.5]decane derivatives and use thereof

Purdue Pharma
26
Substituted indoline derivatives as dengue viral replication inhibitors

Janssen Pharmaceuticals
22
4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

Heptares Therapeutics
19
Azetidine derivatives

Vernalis (R&D)
190
Dopamine D3 receptor antagonists

Indivior
6
Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.

Exonate
1
Pyrazole compounds

Eli Lilly
8
Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Merck Sharpe & Dohme